Steroid-toxicity Insights Roundup
As we continue to mark the 75th anniversary of glucocorticoids and our aspiration to shift steroid-prescribing patterns, the Steritas digital strategies team invites you to the launch of our all-new STOX Digital Platform for steroid-toxicity assessment.
The STOX Digital Platform houses the proprietary algorithms to calculate scores for all clinical outcome assessments in the STOX Suite:
Our new Part 11-enabled digital platform will showcase how licensees from academia and industry can obtain validated results on-demand. The platform offers access across a number of different channels including: a web-based application for bulk data uploads, a REST API for system integrations, and programming language libraries (SAS, R, Python) for statistical analysis. The platform is available in cloud and on-premise implementations.
Please join us on March 14, 2024, 11:00 AM ET/8:00 AM PT. Register now >
Neelam Goyal, MD is a Clinical Associate Professor in Neurology and Neurological Sciences at Stanford and specializes in the diagnosis, management and electrophysiological testing of neuromuscular disorders, with expertise in immune-mediated disorders such as myositis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), and vasculitis.
More than 6.8 million people suffer with inflammatory bowel disease (IBD), many of whom are at risk of increased morbidity due to an overreliance on steroids as a main pillar of treatment.
Recommended by LinkedIn
A new study published in the Journal of Neurological Sciences has highlighted the negative impact steroid-toxicities have on patient quality of life.
Steritas is working toward a world free of steroid dependency, enabling the measurement and monitoring of steroid-toxicity to optimize treatment of inflammatory diseases and improve the quality of patient care around the world.
Learn more at steritas.com.
Sincerely,
Martha Stone
CEO, Steritas